Question 1

What are Inventera’s main contrast-agent pipelines?

Accepted Answer

Inventera holds disease-specific nano-MRI contrast pipelines including INV-002 (musculoskeletal), INV-001 (lymphatic), INV-003 (pancreatobiliary), and INV-00X (cerebrovascular), among others.

Question 2

What is the significance of the INV-002 pipeline?

Accepted Answer

INV-002 targets an unmet diagnostic gap where no approved MRA contrast agent exists for musculoskeletal disease, and is a key pipeline demonstrating clinical validation and commercial potential of Inventera’s platform.

Question 3

Why is INV-002 considered safer than gadolinium agents?

Accepted Answer

INV-002 uses biocompatible iron instead of gadolinium, reducing concerns such as nephrotoxicity and body accumulation seen with gadolinium agents while providing longer-lasting contrast effect.

Question 4

Does Inventera’s pipeline expand into therapeutics?

Accepted Answer

Yes. Inventera extends the platform into therapeutics through Invinity™-Drug Conjugates and Invinity™-ADC, including hydrophobic drug delivery and next-generation ADC development.

Platform-Driven Pipeline

Diagnostics

Therapeutics

IP Strategy

Powered by Invinity™

About Inventera

Investor Relations